Your Messages Inbox
Your Article Summary
See Latest ArticlesAvigen Completes Multi-Center AV650 Phase 2b Spasticity Trial in Patients With Multiple Sclerosis
Avigen, 01/09/09
Avigen, Inc., a biopharmaceutical company innovating therapeutics for neurological care, announced the completion of the double-blind portion of its Phase 2b trial for AV650 (tolperisone HCl) in the treatment of spasticity associated with multiple sclerosis (MS). This Phase 2b spasticity trial is evaluating the safety, tolerability and efficacy of AV650 in MS patients at doses up to 900mg/day for one month followed by an open-label safety extension. The trial is being conducted in top MS centers in Germany and several other European countries.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
b3c newswire, 12/07/09
Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN at 51st ASH Annual Meeting
Allos Therapeutics, 12/07/09
Nplate Data From MDS Studies Presented at ASH
Amgen, 12/07/09
Article Search
Sponsor